\documentclass[aspectratio=169]{beamer}
%\documentclass[handout]{beamer}

% language settings
%\usepackage{fontspec, polyglossia}
%\setdefaultlanguage{magyar}

% common packages
\usepackage{amsmath, multimedia, hyperref, color, multirow}
%\usepackage{graphicx}
\usepackage{xcolor}
\definecolor{BlueGreen}{cmyk}{0.85,0,0.33,0}
\usepackage{url}

% TikZ
\usepackage{tikz}
%\usetikzlibrary{arrows.meta, decorations.pathmorphing, decorations.pathreplacing, shapes.geometric,mindmap}
%\usetikzlibrary{shapes.geometric,fadings,bayesnet}

% beamer styles
\mode<presentation>{
%\usetheme{Madrid}
\usetheme{default}
%\usetheme{Antibes}
%\usecolortheme{beaver}
\usecolortheme{default}
%\usecolortheme{dove}
%\usefonttheme{structureitalicserif}
\setbeamercovered{transparent}
}
\setbeamertemplate{blocks}[rounded][shadow=true]
\AtBeginSubsection[]{
  \begin{frame}<beamer>{Contents}
    \tableofcontents[currentsection,currentsubsection]
  \end{frame}
}
%\useoutertheme[]{tree}

% title, etc
\title{Screening preclinical compounds}
\subtitle{}
\author{Attila Jones}
\date{}

\begin{document}

\titlepage

\begin{frame}[label=chembl-stats]{Preclinical compounds; investigational
  \& approved drugs}
\begin{center}
  \includegraphics[width=0.5\textwidth]{../../../../figures/from-others/chembl-v33-stats.png}

  {\tiny ChEMBL v33}
\end{center}
\end{frame}

\begin{frame}{Network pharmacology based screen of approved drugs}
\begin{columns}[t]
\begin{column}{0.4\textwidth}
  drug-target interaction (DTI) network,...
  

  \includegraphics[scale=1.0]{../../../../figures/by-me/drug-target-disgene-network/drug-target-disgene-network-scores.pdf}
\end{column}

\begin{column}{0.6\columnwidth}
  3 top scoring drugs + network

\includegraphics[width=1.0\columnwidth]{../../../results/2022-09-26-selected-drugs/knowledge-dtn.sif.pdf}
\end{column}
\end{columns}

  {\tiny Jones et al in preparation}
\end{frame}

\begin{frame}{Drug-target interaction networks}
\begin{columns}[t]
\begin{column}{0.6\columnwidth}

  \includegraphics<1>[width=\columnwidth]{../../../../figures/from-others/tanoli-2020-fig2a.jpeg}
  \includegraphics<2>[width=\columnwidth]{../../../../figures/from-others/yildirim-2007-fig2.png}

  %{\tiny Tanoli et al 2020}
\end{column}

\begin{column}{0.4\textwidth}
\begin{itemize}
  \item (overlapping) databases: PubChem, ChEMBL, DrugBank, DGI, DTC,...
  \item DTI (edge) properties: heterogenous, quali/quantitative (pChEMBL, DGI
    scores)
  \item<2> DTI (edge) distro: drug classes, non-uniform missingness, sparseness
\end{itemize}

\end{column}
\end{columns}
\end{frame}


\begin{frame}
\begin{columns}[t]
\begin{column}{0.5\textwidth}

\includegraphics[width=1.0\columnwidth]{../../../../figures/from-others/chembl-v33-stats.png}

{\tiny ChEMBL v33}
\end{column}

\begin{column}{0.5\textwidth}
  \Large

  Main problems with preclinical compounds

\begin{enumerate}
  \item sparseness of DTI $\Rightarrow$ use predicted targets in ChEMBL
  \item computational feasibility
\end{enumerate}

%\includegraphics[width=1.0\columnwidth]{../../../../figures/from-others/goel-2022-fig1.png}

\end{column}
\end{columns}
\end{frame}


\begin{frame}{Brute force vs subsampling (docking as an example task)}
\includegraphics[height=0.8\textheight]{../../../../figures/from-others/goel-2022-fig4.png}
\end{frame}


\end{document}

\begin{columns}[t]
\begin{column}{0.5\textwidth}
\end{column}

\begin{column}{0.5\textwidth}

\end{column}
\end{columns}
